Lorus’ cancer drug granted orphan drug status by EU
Lorus believes this endorsement indicates that the product has the potential to provide efficacy and a significant benefit to patients with this devastating condition. The new status of
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.